Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice

Cancer Science

Volumn 100, Issue 8, 2009, Pages 1510-1519

  Wen, Qing Lian ^a,c   Meng, Mao Bin ^b   Yang, Bo ^c   Tu, Ling Li ^b   Jia, Li ^b   Zhou, Lin ^b   Xu, Yong ^b   Lu, You ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; RECOMBINANT ENDOSTATIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; HISTOPATHOLOGY; LUNG ADENOCARCINOMA; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CARCINOMA; COMBINED MODALITY THERAPY; ENDOSTATINS; HUMANS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650648497     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01193.x     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
2. Li L, Lu F, Zhang S. Analyses of variation trend and short-term detection of Chinese malignant tumor mortality during twenty years. Zhonghua Zhong Liu Za Zhi. 1997; 19: 3-9.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333: 1757-17.
4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001; 7: 987-9.
5. Sharma RA, Harris AL, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol. 2001; 2: 726-32.
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature. 2000; 407: 249-57.
7. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971; 285: 1182-6.
8. Jain RK, Duda DG, Clark JW, Leoffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006; 3: 24-40.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42.
10. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23-47.
11. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR. Tumor oxygenation predicts for the likelihood of distant metastasis in human soft tissue sarcoma. Cancer Res. 1996; 56: 941-3.
12. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996; 379: 88-91.
13. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277-85.
14. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer dose not induce acquired drug resistance. Nature. 1997; 390: 404-7.
15. Han Q, Fu Y, Zhou H, He Y, Luo Y. Contributions of Zn (II)-binding to the structural stability of endostatin. FEBS Lett. 2007; 581: 3027-32.
16. Sun Y, Wang J, Liu Y, et al. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. Annual ASCO Meeting. 2005. May in FL, USA. (Abstract 7134).
17. State Food and Drug Administration. 2005. Available from http://app1.sfda.gov.cn/datasearch/face3/base.jsp. [Accessed 12 September 2008].
18. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res. 2003; 9: 1957-71.
19. Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol. 2003; 21: 2760-76.
20. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol. 2006; 16: 45-50.
21. Itasaka S, Komaki R, Herbst RS, et al. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys. 2007; 67: 870-8.
22. Olive PL, Durand RE, Raleigh JA, et al. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer. 2000; 83: 1525-31.
23. Leong KG, Hu X, Li L, et al. Activated notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Bio. 2002; 22: 2830-41.
24. Hanna NN, Seetharam S, Mauceri HJ, et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000; 6: 287-93.
25. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001; 98: 1904-13.
26. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996; 2: 689-92.
27. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002; 20: 3804-14.
28. Teicher BA, Dupuis N, Kusomoto T, et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Rad Oncol Invest. 1995; 2: 269-76.
29. Rockwell S, Moulder JE. Hypoxic fractions of human tumors xenografted into mice: A review. Int J Radiat Oncol Biol Phys. 1990; 19: 197-202.
30. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol. 2001; 24: 467-72.
31. Rofstad EK, Mathiesen B, Kindem K, et al. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006; 66: 6699-707.
32. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56: 4509-15.
33. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999; 53: 113-17.
34. Brem S, Cotran R, Folkman J. Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst. 1972; 48: 347-56.
35. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogeneic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002; 94: 883-93.
36. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2003; 2: 727-39.
37. Plum SM, Hanson AD, Volker KM, et al. Synergistic activity of recombinant human endostatin in combination with adriamycin: Analysis of in.vitro activity on endothelial cells and in.vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res. 2003; 9: 4619-26.
38. Sun L, Ye HY, Zhang YH, Guan YS, Wu H. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol. 2007; 13: 6115-18.
39. Celik I, Surucu O, Dietz C, et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005; 65: 11 044-50.
40. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003; 21: 223-31.
41. Herbst RS, Mullani N, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002; 20: 3804-14.
42. Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res. 2004; 10: 33-42.
43. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res. 2003; 9: 377-82.
44. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA. 2004; 101: 8005-10.
45. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell. 2004; 13: 649-63.